Amgen (NASDAQ:AMGN) Given New $200.00 Price Target at Rothschild & Co Redburn

Amgen (NASDAQ:AMGN) had its price objective boosted by Rothschild & Co Redburn from $180.00 to $200.00 in a report released on Wednesday,MarketScreener reports. The brokerage currently has a sell rating on the medical research company’s stock.

Several other research analysts have also recently issued reports on the company. Guggenheim raised their target price on Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Royal Bank Of Canada lifted their price objective on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Wells Fargo & Company increased their price target on Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Finally, Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $349.75.

Amgen Stock Up 1.7%

AMGN stock opened at $379.73 on Wednesday. The stock has a market capitalization of $204.70 billion, a P/E ratio of 26.69, a P/E/G ratio of 3.82 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen has a 1-year low of $261.43 and a 1-year high of $385.12. The business has a fifty day moving average price of $340.91 and a 200-day moving average price of $315.28.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts forecast that Amgen will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s dividend payout ratio is presently 70.84%.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently modified their holdings of AMGN. Strive Financial Group LLC purchased a new stake in shares of Amgen in the 4th quarter worth approximately $2,409,000. Ameriflex Group Inc. raised its stake in Amgen by 295.2% in the fourth quarter. Ameriflex Group Inc. now owns 7,299 shares of the medical research company’s stock worth $2,389,000 after buying an additional 5,452 shares in the last quarter. First Commonwealth Financial Corp PA purchased a new stake in Amgen during the fourth quarter worth $227,000. Blue Sparrow LLC DE bought a new stake in Amgen during the 4th quarter valued at $10,609,000. Finally, Mercer Global Advisors Inc. ADV increased its holdings in shares of Amgen by 19.1% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 144,357 shares of the medical research company’s stock valued at $46,731,000 after acquiring an additional 23,179 shares during the period. Institutional investors own 76.50% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.